06.20.14
Kappa Bioscience AS, Oslo, Norway, has obtained Therapeutic Goods Australia (TGA) approval for the use of synthetic Vitamin K2 MK-7 in complementary medicines in Australia.
With immediate effect, Australian manufacturers and brand marketers will be permitted to use K2VITAL, the company’s proprietary vitamin K2 MK-7, as an ingredient to boost bone and cardiovascular-based health claims. The ingredient will be brought to market through our Australian & New Zealand agent, Nutrition Connect Pty Ltd.
This approval is a result of a file submission wholly owned, prepared and supported by Kappa Bioscience AS and is restricted to organic synthesis and high purity profile vitamin K2 MK-7, as is achieved with K2VITAL.
Kappa Bioscience AS has teamed up with Alpha Laboratories (NZ) Ltd as the 3rd party manufacturer for formulations containing Vitamin K2 MK-7 to allow a quick adoption into the market place. Alpha Laboratories have several complementary medicine formulations ready to be marketed. All of those come fully documented and are currently undergoing shelf-life studies, including selected formulations in zone iv b trials.
With immediate effect, Australian manufacturers and brand marketers will be permitted to use K2VITAL, the company’s proprietary vitamin K2 MK-7, as an ingredient to boost bone and cardiovascular-based health claims. The ingredient will be brought to market through our Australian & New Zealand agent, Nutrition Connect Pty Ltd.
This approval is a result of a file submission wholly owned, prepared and supported by Kappa Bioscience AS and is restricted to organic synthesis and high purity profile vitamin K2 MK-7, as is achieved with K2VITAL.
Kappa Bioscience AS has teamed up with Alpha Laboratories (NZ) Ltd as the 3rd party manufacturer for formulations containing Vitamin K2 MK-7 to allow a quick adoption into the market place. Alpha Laboratories have several complementary medicine formulations ready to be marketed. All of those come fully documented and are currently undergoing shelf-life studies, including selected formulations in zone iv b trials.
